BRPI1007018B8 - composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. - Google Patents

composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto.

Info

Publication number
BRPI1007018B8
BRPI1007018B8 BRPI1007018A BRPI1007018A BRPI1007018B8 BR PI1007018 B8 BRPI1007018 B8 BR PI1007018B8 BR PI1007018 A BRPI1007018 A BR PI1007018A BR PI1007018 A BRPI1007018 A BR PI1007018A BR PI1007018 B8 BRPI1007018 B8 BR PI1007018B8
Authority
BR
Brazil
Prior art keywords
compound
adenosine
pharmaceutical composition
receptors
receptor binding
Prior art date
Application number
BRPI1007018A
Other languages
English (en)
Inventor
Mayer Stanislas
Schann Stephan
Original Assignee
Domain Therapeutics
Kaldi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domain Therapeutics, Kaldi Pharma filed Critical Domain Therapeutics
Publication of BRPI1007018A2 publication Critical patent/BRPI1007018A2/pt
Publication of BRPI1007018B1 publication Critical patent/BRPI1007018B1/pt
Publication of BRPI1007018B8 publication Critical patent/BRPI1007018B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto, composição farmacêutica, e, uso de um composto. a presente invenção fornece novos compostos com alta afinidade por receptores a2a de adenosina. também fornece antagonistas de receptores a2a de adenosina e seu uso como medicamentos para o tratamento e/ou profilaxia de doenças e distúrbios onde a inativação parcial ou total de caminhos de sinalização de receptores a2a de adenosinas devem ser benéficos tal como mal de alzheimer, mal de parkinson, déficit de atenção e distúrbios de hiperatividade (adhd), doença de huntington, neuroproteção, esquizofrenia, ansiedade e dor. a presente invenção ainda diz respeito às composições farmacêuticas contendo tais novos compostos com alta afinidade por receptores a2a de adenosina e seu uso para o tratamento e/ou profilaxia de doenças e distúrbios onde a inativação parcial ou tal de receptores a2a de adenosina deve ser benéfica.
BRPI1007018A 2009-01-26 2010-01-25 composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. BRPI1007018B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09360007.0 2009-01-26
EP20090360007 EP2210891A1 (en) 2009-01-26 2009-01-26 New adenosine receptor ligands and uses thereof
PCT/IB2010/000416 WO2010084425A1 (en) 2009-01-26 2010-01-25 New adenosine receptor ligands and uses thereof

Publications (3)

Publication Number Publication Date
BRPI1007018A2 BRPI1007018A2 (pt) 2016-03-29
BRPI1007018B1 BRPI1007018B1 (pt) 2020-03-10
BRPI1007018B8 true BRPI1007018B8 (pt) 2021-05-25

Family

ID=40669959

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007018A BRPI1007018B8 (pt) 2009-01-26 2010-01-25 composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto.

Country Status (15)

Country Link
US (1) US9029393B2 (pt)
EP (2) EP2210891A1 (pt)
JP (2) JP5680553B2 (pt)
CN (1) CN102365280B (pt)
AU (1) AU2010207494B2 (pt)
BR (1) BRPI1007018B8 (pt)
CA (1) CA2750449C (pt)
CY (1) CY1114329T1 (pt)
DK (1) DK2391625T3 (pt)
ES (1) ES2419280T3 (pt)
IL (1) IL214167A (pt)
NZ (1) NZ594405A (pt)
PT (1) PT2391625E (pt)
WO (1) WO2010084425A1 (pt)
ZA (1) ZA201105791B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2807198A1 (en) * 2010-08-03 2012-02-09 Graffinity Pharmaceuticals Gmbh Ligands for antibody and fc-fusion protein purification by affinity chromatography
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
WO2013033620A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN104395335A (zh) 2012-02-08 2015-03-04 努艾利克斯德国股份有限公司 用于抗体和Fc-融合蛋白亲和色谱IV纯化的配体
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
AU2017360939B2 (en) * 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
ES2953349T3 (es) * 2017-05-05 2023-11-10 Arcus Biosciences Inc Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
LT3796975T (lt) 2018-05-22 2023-12-11 Orsobio, Inc. Sulfonilaminobenzamido dariniai
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210083287A (ko) 2018-10-25 2021-07-06 메르크 파텐트 게엠베하 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
KR20210083293A (ko) 2018-10-25 2021-07-06 메르크 파텐트 게엠베하 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
TWI834795B (zh) 2019-01-08 2024-03-11 日商杏林製藥股份有限公司 15-pgdh抑制劑
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3917911A1 (en) * 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
MX2021009439A (es) * 2019-02-07 2021-11-12 Beigene Ltd Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240066027A1 (en) * 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
GB202019622D0 (en) * 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN115093372B (zh) * 2022-06-16 2023-05-30 安徽工程大学 一种咪唑衍生物的合成方法
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764387B1 (fr) 1997-06-05 1999-07-23 Centre Nat Rech Scient Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand
JP2003525291A (ja) * 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
JP2005530788A (ja) * 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP2005126374A (ja) * 2003-10-24 2005-05-19 Kissei Pharmaceut Co Ltd 新規なアデノシンａ２ａ受容体拮抗剤
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
CA2591125A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
US7557103B2 (en) * 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8569512B2 (en) * 2009-03-23 2013-10-29 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
WO2013033620A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
WO2013134219A1 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof

Also Published As

Publication number Publication date
PT2391625E (pt) 2013-07-05
EP2391625B1 (en) 2013-05-01
JP2012515759A (ja) 2012-07-12
CN102365280B (zh) 2014-10-29
US20110288074A1 (en) 2011-11-24
WO2010084425A1 (en) 2010-07-29
AU2010207494A1 (en) 2011-08-25
EP2210891A1 (en) 2010-07-28
NZ594405A (en) 2013-09-27
JP5680553B2 (ja) 2015-03-04
CA2750449C (en) 2018-03-13
ES2419280T3 (es) 2013-08-20
IL214167A0 (en) 2011-08-31
US9029393B2 (en) 2015-05-12
JP2015110599A (ja) 2015-06-18
ZA201105791B (en) 2014-01-29
IL214167A (en) 2017-09-28
JP6201098B2 (ja) 2017-09-27
BRPI1007018B1 (pt) 2020-03-10
BRPI1007018A2 (pt) 2016-03-29
CY1114329T1 (el) 2016-08-31
AU2010207494B2 (en) 2015-12-03
CN102365280A (zh) 2012-02-29
CA2750449A1 (en) 2010-07-29
HK1167392A1 (en) 2012-11-30
DK2391625T3 (da) 2013-07-01
EP2391625A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
BRPI1007018B8 (pt) composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto.
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
HN2012001265A (es) Modulares alostericos positivos de receptores mi1 de la quinolina amida
BR112012010253A8 (pt) compostos de pirimidina como moduladores do receptor delta opioide
BR112015015468B8 (pt) Composto, e, composição farmacêutica
BR112013002250A2 (pt) composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BRPI1014522B8 (pt) anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BR112015001028A2 (pt) antagonistas de receptor 5-ht3
BR112014024479A8 (pt) Formulações farmacêuticas compreendendo antagonistas de c-cr3
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BR112013004721A2 (pt) "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112014001714A2 (pt) derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
BR112014011262A8 (pt) compostos substituídos de carboxamida à base de pirazolila substituída e derivados de ureia, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: KALDI PHARMA (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2864 DE 25-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.